<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83042">
  <stage>Registered</stage>
  <submitdate>5/08/2008</submitdate>
  <approvaldate>5/09/2008</approvaldate>
  <actrnumber>ACTRN12608000445370</actrnumber>
  <trial_identification>
    <studytitle>Developing a research base for Intravenous Peripheral catheter resites: the DRIP Trial</studytitle>
    <scientifictitle>Randomised Controlled Trial of routine versus clinically indicated resite of peripheral intravenous devices in hospitalised patients to prevent phlebitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>phlebitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients in this study are generic medical/surgical/oncology hospitalised patients who require a peripheral intravenous device. Patients will have their peripheral intravenous devices (IVs) removed after 72-96 hours of use a new IV resited in another vein. This will continue for the course of IV therapy, that is as long as IV therapy is required.</interventions>
    <comparator>Patients will have their intravenous devices (IVs) left in situ for as long as treatment continues unless they have phlebitis or IV malfunction. The overall duration is for the course of treatment with an IV e.g. for a course of antibiotics or rehydration.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phlebitis during catheterisation or up to 48 hours after catheter removal. Phlebitis defined as 2 or more of: pain, tenderness, erythema, swelling, purulence, and/or palpable venous cord.</outcome>
      <timepoint>Daily while cannulae is in situ and for 48 hours post removal</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Catheter related bloodstream infection: Bacteremia/fungemia with more than 1 positive blood culture obtained from a peripheral vein, clinical manifestations of infections (i.e.fever, chills, and/or hypotension), and no apparent source for the BSI except the catheter. One of the following should be present: a positive semiquantitative (&gt;15 colony forming units(CFU) /catheter segment) or quantitative (&gt;103 CFU/catheter segment catheter)
culture whereby the same organism (species and antibiogram) is isolated from the catheter segment and peripheral blood; simultaneous quantitative blood cultures with a &gt;5:1 ratio IV versus peripheral; differential period of IV culture versus peripheral blood culture positivity of &gt;2 hours.</outcome>
      <timepoint>Daily while cannulae is in situ or for 48 hours post removal</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Scheduled or expected to have a peripheral IV in situ for 4 days or more, written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>current bacteraemia, planned removal of IV within 24 hours, IV already in situ for more than 48hrs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>computer generated allocation provided by electronic data collection device. Allocation is concealed until the patient is randomised</concealment>
    <sequence>computer generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate>20/05/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/10/2009</actualenddate>
    <samplesize>3300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <postcode>4029 - Royal Brisbane Hospital</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>Research Centre for Clinical and Community Practice Innovation, Nathan Campus 170 Kessels Road Nathan QLD 4111</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>GPO Box 1421 Canberra, ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Brisbane and Women's Hospital</fundingname>
      <fundingaddress>1 Butterfield St, Herston QLD 4029</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Princess Alexandra Hospital</fundingname>
      <fundingaddress>199 Ipswich Rd, Woolloongabba QLD 4102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Gold Coast Hospital</fundingname>
      <fundingaddress>108 Nerang St Southport QLD 4215</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Griffith University</fundingname>
      <fundingaddress>Nathan Campus, 170 Kessels rd, Nathan QLD 4111</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In Australia each year ten million IV drips are inserted in patients arms or in the backs of their hands to give fluid and medications.
Many drips are routinely replaced every few days in the hope that this reduces infection, however preliminary research suggests it would be better and more cost effective to leave them alone. That would save patients the pain of another needle as well as interruption to treatment. It would save doctors and nurses time, and reduce waste from plastic disposables. The research will provide the evidence to know one way or the other whether IV drips should be routinely changed or left alone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>1 Butterfield St herston QLD 4029</ethicaddress>
      <ethicapprovaldate>10/12/2007</ethicapprovaldate>
      <hrec>2007/186</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Prof Claire Rickard</name>
      <address>Griffith University
Nathan Campus
170 Kessels Road
Nathan QLD 4111</address>
      <phone>07 3735 6460</phone>
      <fax />
      <email>c.rickard@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Prof Claire Rickard</name>
      <address>Griffith University
170 Kessels Road, Nathan QLD 4111</address>
      <phone>07 3735 6460</phone>
      <fax />
      <email>c.rickard@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Rickard</name>
      <address>Griffith University 170 Kessels Road, Nathan QLD 4111	</address>
      <phone>+61 7 3735 6460</phone>
      <fax />
      <email>c.rickard@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>